New antibody treatment could tame rare brain disease Flare-Ups
NCT ID NCT07182409
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether monoclonal antibodies can safely and effectively treat acute attacks of neuromyelitis optica spectrum disorder (NMOSD), a rare disease that causes inflammation in the eyes and spinal cord. Researchers will enroll 40 adults experiencing a recent flare-up and measure changes in disability over six months. The goal is to find better ways to control these attacks and improve recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- monoclonal antibody
- What this could lead to
- If successful, this could point toward a more effective way to treat acute attacks of NMOSD, potentially reducing long-term disability.
- What could go wrong
- This is a small, early-stage study with only 40 participants, so results may not apply to everyone. The treatment may not work better than existing options or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NMOSD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- New hope for NMOSD patients: drug aims to slash relapse rate
- Major trial to determine best drug for rare autoimmune disease
- Immune reset: CAR-T therapy targets lupus, MS, and more
- New registry to monitor Real-World effects of NMOSD treatments
- Hormone clues sought in rare nerve disease